Fluoroquinolones for the treatment of pulmonary tuberculosis

Drugs

Volumn 67, Issue 14, 2007, Pages 2077-2099

  Moadebi, Susanne ^a   Harder, Curtis K ^b   Fitzgerald, Mark J ^a,c   Elwood, Kevin R ^a,b   Marra, Fawziah ^a,b  

^a BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Centre for Clinical Epidemiology and Evaluation   (Canada)

Author keywords

Ciprofloxacin, therapeutic use; Fluoroquinolones, therapeutic use; Gatifloxacin, therapeutic use; Levofloxacin, therapeutic use; Moxifloxacin, therapeutic use; Ofloxacin, therapeutic use; Pulmonary tuberculosis, treatment

Indexed keywords

AMINOSALICYLIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PEFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; SPARFLOXACIN; STREPTOMYCIN; THIOACETAZONE;

ABSENCE OF SIDE EFFECTS; ACUTE KIDNEY FAILURE; ADD ON THERAPY; AGEUSIA; CASE STUDY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL STUDY; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; LUNG TUBERCULOSIS; MEDLINE; MONOTHERAPY; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PHOTOSENSITIVITY; RASH; REVIEW; SINGLE DRUG DOSE; SPUTUM CULTURE; SPUTUM SMEAR; STATISTICAL ANALYSIS; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VERTIGO; VOMITING;

MYCOBACTERIUM TUBERCULOSIS;

EID: 34948893503     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767140-00007     Document Type: Review

References (47)

1. Dye C, Scheele S, Dolin P, et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO global surveillance and monitoring project. JAMA 1999; 282: 677-86
2. Raviglione MC, Snider Jr DE, Kochi A. Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic. JAMA 1995; 273: 220-6
3. WHO. The world health report 2004: changing history [online] Available from URL: http://www.who.int/whr/2004/en/index.html. [Accessed 2006 May 2]
4. WHO. Global tuberculosis control: surveillance, planning, financing [online]. Available from URL: http://www.who.int/tb/publications/global_report/ 2006/en/index.html. [Accessed 2006 May 2]
5. Dye C. Global epidemiology of tuberculosis. Lancet 2006; 367: 938-40
6. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-62
7. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin: a meta-analysis. Chest 1991; 99: 465-71
8. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003; 3: 432-42
9. Berning SE. The role of fluoroquinolones in tuberculosis today. Drugs 2001; 61: 9-18
10. Guerrant RL, Van Gilder T, Steiner TS, et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 2001; 32: 331-51
11. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730-54
12. Workowski KA, Berman SM. CDC sexually transmitted diseases treatment guidelines. Clin Infect Dis 2002; 35: S135-7
13. Gillespie SH, Kennedy N. Fluoroquinolones: a new treatment for tuberculosis? Int J Tuberc Lung Dis 1998; 2: 265-71
14. Aubry A, Pan XS, Fisher LM, et al. Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity. Antimicrob Agents Chemother 2004; 48: 1281-8
15. Ziganshina LE, Vizel AA, Squire SB. Fluoroquinolones for treating tuberculosis. Cochrane Database Syst Rev 2005; (3): CD004795
16. Kennedy N, Fox R, Kisyombe GM, et al. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis. Am Rev Respir Dis 1993; 148: 1547-51
17. Kennedy N, Fox R, Uiso L, et al. Safety profile of ciprofloxacin during long-term therapy for pulmonary tuberculosis. J Antimicrob Chemother 1993; 32: 897-902
18. Kennedy N, Berger L, Curram J, et al. Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis. Clin Infect Dis 1996; 22: 827-33
19. Kohno S, Koga H, Kaku M, et al. Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis. Chest 1992; 102: 1815-8
20. Mohanty KC, Dhamgaye TM. Controlled trial of ciprofloxacin in short-term chemotherapy for pulmonary tuberculosis. Chest 1993; 104: 1194-8
21. Saigal S, Agarwal SR, Nandeesh HP, et al. Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: a preliminary report. J Gastroenterol Hepatol 2001; 16: 1028-32
22. Burman WJ, Goldberg S, Johnson JL, et al. Moxifloxacin versus ethambutol in the first two months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006 Aug 1; 174 (3): 331-8
23. el-Sadr WM, Perlman DC, Matts JP, et al. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS clinical trials group (ACTG). Clin Infect Dis 1998; 26: 1148-58
24. Yang CK, Lin HC, Lee KY, et al. The effects of ciprofloxacin on chest radiographic regression in patients with drug intolerance or resistant tuberculosis. Chang Gung Med J 2004; 27: 292-9
25. Chan ED, Laurel V, Strand MJ, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004; 169: 1103-9
26. Marra F, Marra CA, Moadebi S, et al. Levofloxacin treatment of active tuberculosis and the risk of adverse events. Chest 2005; 128: 1406-13
27. Hong Kong Chest Service/British Medical Research Council. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Tuber Lung Dis 1992; 73: 59-67
28. Tuberculosis Research Centre, Indian Council of Medical Research. Shortening short course chemotherapy: a randomised clinical trial for treatment of smear positive pulmonary tubeculosis with regimens using ofloxacin in the intensive phase. Ind J Tub 2002; 49: 27-38
29. Bergstermann H, Ruchardt A. Ciprofloxacin once daily versus twice daily for the treatment of pulmonary tuberculosis. Infection 1997; 25: 227-32
30. Berning SE, Madsen L, Iseman MD, et al. Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections. Am J Respir Crit Care Med 1995; 151: 2006-9
31. Kahana LM, Spino M. Ciprofloxacin in patients with mycobacterial infections: experience in 15 patients. DICP 1991; 25: 919-24
32. Lubasch A, Erbes R, Mauch H, et al. Sparfloxacin in the treatment of drug resistant tuberculosis or intolerance of first line therapy. Eur Respir J 2001; 17: 641-6
33. Mangunnegoro H, Hudoyo A. Efficacy of low-dose ofloxacin in the treatment of multidrug-resistant tuberculosis in Indonesia. Chemotherapy 1999; 45 Suppl. 2: 19-25
34. Palmero DJ, Ambroggi M, Brea A, et al. Treatment and follow-up of HIV-negative multidrug-resistant tuberculosis patients in an infectious diseases reference hospital, Buenos Aires, Argentina. Int J Tuberc Lung Dis 2004; 8: 778-84
35. Park SK, Lee WC, Lee DH, et al. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea. Int J Tuberc Lung Dis 2004; 8: 361-8
36. Rao S. Uncontrolled trial of sparfloxacin in retreatment of pulmonary tuberculosis. Respirology 2004; 9: 402-5
37. Rao S. An uncontrolled trial of pefloxacin in the retreatment of patients with pulmonary tuberculosis. Tuber Lung Dis 1995; 76: 219-22
38. Singla R, Gupta S, Gupta R, et al. Efficacy and safety of sparfloxacin in combination with kanamycin and ethionamide in multidrug-resistant pulmonary tuberculosis patients: preliminary results. Int J Tuberc Lung Dis 2001; 5: 559-63
39. Suo J, Yu MC, Lee CN, et al. Treatment of multidrug-resistant tuberculosis in Taiwan. Chemotherapy 1996; 42 Suppl. 3: 20-3
40. Telzak EE, Chirgwin KD, Nelson ET, et al. Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS clinical trials group (ACTG), National Institutes for Health. Int J Tuberc Lung Dis 1999; 3: 337-43
41. Yew WW, Chau CH, Wong PC, et al. Ciprofloxacin in the management of pulmonary tuberculosis in the face of hepatic dysfunction. Drugs Exp Clin Res 1995; 21: 79-83
42. Yew WW, Kwan SY, Ma WK, et al. In-vitro activity of ofloxacin against mycobacterium tuberculosis and its clinical efficacy in multiple resistant pulmonary tuberculosis. J Antimicrob Chemother 1990; 26: 227-36
43. Yew WW, Lee J, Wong PC, et al. Tolerance of ofloxacin in the treatment of pulmonary tuberculosis in presence of hepatic dysfunction. Int J Clin Pharmacol Res 1992; 12: 173-8
44. Yew WW, Chan CK, Chau CH, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin- containing regimens. Chest 2000; 117: 744-51
45. Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacintion-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2004; 169: 421-6
46. US FDA. Bristol-Myers Squibb's "Dear Health Care Provider" letter for tequin (gatifloxacin), 2006 Feb 15 [online]. Available from URL: http://www.fda.gov/medwatch/safety/2006/safety06.htm#Tequin. [Accessed 2007 Feb 16]
47. Canadian Adverse Reaction Newsletter. Levofloxacin: dysglycemia and liver disorders. [online]. Available from URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/ bulletin/index_e.html. [Accessed 2007 Feb 16]